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Background: It is debated whether interferon-based therapy (IBT) would affect the incidence of active tuberculosis
(TB) among hepatitis C virus (HCV) infected patients. Although some case reports have demonstrated a possible
association, the results are currently inconclusive. Therefore, we conducted a nation-wide population study to
investigate the incidence of active TB in HCV infected patients receiving IBT in Taiwan.
Methods: This 9-year cohort study was based on the Longitudinal Health Insurance Database 2000 (LHID 2000)
consisting of 1,000,000 beneficiaries randomly selected from all Taiwan National Health Insurance enrollees in 2000
( >23.7 million). This insurance program covers all citizens in Taiwan. We conducted a retrospective cohort study that
identified subjects with HCV infection. IBTs were defined as regimens that included interferon α, peginterferon α2a and
peginterferon α2b for at least 2 months. Among them, 621 subjects received IBT, and 2,460 age- and gender-matched
subjects were enrolled for analysis. The Cox proportional hazards models were used to estimate the hazard ratio (HR)
for active TB, and associated confidence intervals (CIs), comparing IBT cohort and untreated cohort. The endpoint in this
study was whether an enrolled subject had a new diagnosis of active TB.
Results: During the 9-year enrollment period, the treated and untreated cohorts were followed for a mean (± SD)
duration of 6.97 ± 0.02 years and 8.21 ± 0.01 years, respectively. The cumulative incidence rate of active TB during this
study period was 0.150 and 0.151 per 100 person-years in the IBT treated and untreated cohorts, respectively. There
was no significant difference in the incidence of active TB in either cohort during a 1-year follow-up (Adjusted
Hazard Ratio (AHR): 2.81, 95% Confidence Interval (95% CI): 0.61–12.98) or the long-term follow-up (AHR: 1.02, 95% CI:
0.28 – 3.78). The Cox proportional hazards model demonstrated that IBT was not a risk factor for active TB . The only risk
factor for active TB was the occurrence of hepatic encephalopathy.
Conclusion: Our results showed that IBT is associated with increased hazard of active TB in HCV infected patients in
1-year follow-up; however, the effect sizes were not statistically significant.
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An estimated 170 million people are chronically infected
with Hepatitis C virus (HCV), and 3 to 4 million people
are newly infected each year [1]. HCV infection is the
major cause of chronic liver disease worldwide and can
lead to cirrhosis and hepatocellular carcinoma [1]. There-
fore, effective anti-HCV therapies are recommended by
national and international guidelines [2]. Pegylated inter-
ferons plus ribavirin have been used as the standard treat-
ment of HCV infection for decades [3,4].
Interferons (IFNs) are a group of structurally related cy-
tokines that are important in antiviral activities [5]. There
are two types of IFNs, type I and type II. Type I IFNs, such
as IFN-α/β, are produced in most cell types in response to
microorganism infections and play a crucial role in innate
immune activity against viruses [6]. The type II IFN, INF-γ,
is the main mediator of the type I immune response and is
essential in the control of mycobacterial infection in both
animal models and humans [7]. In contrast to IFN-γ, the
role of INF-α/ß in tuberculosis (TB) is controversial. In an
in vitro study, IFN-ß was shown to improve bacillus
Calmette-Guerin (BCG) immunogenicity by increasing hu-
man dendritic cell maturation [8]. In an animal model, type
I IFN limited the number of target cells that M.tuberculosis
infected in the lungs [9]. Early clinical pilot studies demon-
strated that aerosolized IFN-α combined with standard
therapy for pulmonary TB would lead to better clinical
outcomes [10,11]. However, some studies showed that type
I IFNs promoted, rather than inhibited, mycobacterial in-
fection. In an in vitro model, type I IFNs impaired the abil-
ity of human macrophages to control the growth of M.
bovis BCG and M. avium intracellulare complex [12,13].
In an animal model, Manca et al. reported that type I IFNs
enhanced the virulence of M. tuberculosis by the suppres-
sion of the Th1 type immune responses. In addition, the
treatment of TB infected mice with IFN-α/β increases lung
bacterial loads, resulting in reduced survival [14]. Together,
these studies indicate that the role of type I IFNs in myco-
bacterial infections is still inconclusive.
The side effects of IFNs include fatigue, influenza-like
symptoms, hematological abnormalities, and neuropsychi-
atric symptoms [15]. Pulmonary manifestations, including
sarcoidosis, interstitial pneumonitis and bronchiolitis oblit-
erans organizing pneumonia, are considered rare events
[16,17]. Although altered cellular immunodeficiency is as-
sociated with a higher incidence of various infections, TB
has rarely been reported during HCV treatment [18-22].
This may be because the people receiving interferon-based
therapy (IBT) for HCV were mostly located in countries
with low TB incidence rates; this creates a difficulty in
identifying an association between IBT and active TB.
Taiwan is a hyperendemic area of chronic liver diseases
and has an HCV seroprevalence ranging from 0.4 to
10.5%, depending different geographic areas [23]. BecauseHCV infection can lead to fetal comorbidity, the Bureau of
Taiwan National Health Insurance (NHI) has reimbursed
IBT since 2003. Taiwan is also an endemic TB area with an
intermediate burden of TB. In 2008, 2009 and 2010, the in-
cidence rates of TB in Taiwan were 57.8, 57.2 and 54.5 per
100,000 population, respectively [24]. Therefore, this study
used a longitudinal Health Insurance Database 2000 (LHID
2000) that included a nationally representative population,
and used an epidemiological approach to evaluate whether
IBT is a risk factor for the development of active TB during
January 2000 to December 2009.
Methods
Study sample
National Health Insurance (NHI) is a single-payer compul-
sory program that has been implemented in Taiwan since
1995 and covers all forms of health care for the residents
of Taiwan [25]. All citizens who have established a regis-
tered domicile for at least 4 months in the Taiwan area
should be enrolled in the NHI. There are approximately
23,720,000 individuals in this program. The NHI compre-
hensively includes a claims database, including ambulatory
care, outpatient services, inpatient services and prescrip-
tion drugs.
We used a database (LHID2000) containing one million
randomly selected subjects from the Taiwan National
Health Insurance Research Database (NHIRD), which was
developed for research purposes. A systematic, random
sampling method was used to build this representative
database of 1,000,000 NHI enrollees. There were no statis-
tically significant differences in age, sex, or healthcare costs
between the sample group and all the enrollees. This data
set spans from January 2000 through December 2009 and
includes all claims data for these 1,000,000 individuals.
Ethics statement
The identification numbers of all of the subjects in the
NHRI databases were encrypted to protect the privacy of
the individuals. All researchers who used the NHIRD and
its data subsets were required to sign a written agreement
declaring that they had no intention of attempting to ob-
tain information that could potentially violate the privacy
of patients or care providers. This study was approved
by the Institutional Ethics Review Board of Kaohsiung
Medical University Hospital (Kaohsiung, Taiwan) (IRB No
20130067).
Study design and population-based surveillance methods
This study used a retrospective cohort study design to
evaluate the association between IBT and TB events.
This study enrolled patients who were 20 or older from
this database (LHID2000).
The Taiwan NHIRD did not contain direct laboratory
results (such as biochemical data, viral genotype, viral
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able to identify the HCV infected patients based on la-
boratory diagnostic criteria. With approval from the
NHRI, we were able to use the scrambled patient identi-
fication numbers to interlink files, including registry of
medical facilities, details of inpatient orders, ambulatory
care, and prescriptions.
The definition of HCV infection was based on individ-
uals who had at least two service claims of ambulatory
or inpatient care for the treatment of HCV between
2000 and 2008. For only once service claim (The diagno-
sis coding of NHI in Taiwan is performed according to
the International Classification of Disease, 9th Revision,
Clinical Modification (ICD-9-CM) diagnostic criteria.)
would overestimate the diagnosis of HCV. Therefore, we
used at least two service claims of ambulatory or in-
patient treatment care to identify this group. (HCV in-
fected patients) [26]. We defined HCV by compatibleFigure 1 Study flow chart for the enrollment of participants.ICD-9-CM codes of HCV in 070.41, 070.44, 070.51,
070.54, and V02.62.
A total of 12,547 subjects with ICD-9-CM codes of
HCV were identified. Furthermore, we excluded patients
who were diagnosed as having HCV on only 1 occasion
(n = 3,877), who were below 20 years old (n = 77) and
who had a history of TB diagnosis codes (ICD-9
code:010–018) before the first HCV coding and at the
same time as the first HCV coding (n = 281). Therefore,
8,312 patients with a diagnosis coding of HCV on at
least two medical claims were enrolled (Figure 1).
Definition of study cohorts: cohorts treated and not
treated with IBT
Combination regimens with peginterferon α (either 2a
or 2b) and ribavirin have been introduced for treating
HCV infection in Taiwan since October 1, 2003. Gener-
ally, antiviral therapy was initiated as peginterferon α2a
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terferon α2b (1.5 μg /kg per week) combined with ribavi-
rin (800 to 1,200 mg per day). The duration of treatment
ranged from 16 to 48 weeks, depending on viral geno-
type, serum viral load, clinical response, and patient tol-
erability [4].
The treated cohort was comprised of individuals who
had received IBT; these individuals were identified from
the database using the drug codes for interferon α,
peginterferon α2a and peginterferon α2b. Most of the
subjects (99.36 %) had received interferon combined
with ribavirin treatment in this study. Patients who had
received IBT before HCV diagnosis coding index date
were excluded (n = 22). Because NHI in Taiwan reim-
bursed chronic HCV infected patients 4–6 months of
interferon or 6 months of pegylated interferon-based
treatment during 2000–2008, and most patients who did
not achieve early virologic response after 3 months of
treatment discontinued IBT [3,4,27], we selected patients
receiving ≧2 months of IBT into our analyses(IBT
treated cohort) and patients who had received IBT for a
period of <2 months were excluded (n = 77). For those
patients who had received IBT≧ 2 months (n = 621) be-
tween 2000 and 2008 were grouped into the treated co-
hort. The first day of prescription use for the treatment
of HCV was assigned as the index date.
Those patients who did not receive IBT between 2000
and 2008 were designated as the non-treated cohort (n =
7587). We selected 2,460 control subjects from the non-
treated cohort. 95.98% of the IBT treated subjects were
matched at a ratio of 1:4 with the non-treated cohort in
terms of age, sex and the year and month of the index
visit. The control subjects did not include patients who
had TB before their index date. Furthermore, patients who
had a diagnosis of TB before receiving follow-up in both
cohorts were excluded (n = 5).
Study endpoints and adjustment for confounding factors
The endpoint in this study was whether an enrolled sub-
ject had a new diagnosis of TB. The IBT and non-treated
cohorts were both tracked from the date of selection until
the end of 2009 or until loss to follow-up (i.e., withdrawing
from the health insurance program) to identify new TB
events.
The definition of active TB
We defined active TB as at least one outpatient visit or
one hospital admission during the follow-up period with
ICD-9-CM codes of TB (010–018) plus the prescription of
more than two anti-tuberculosis medications (i.e., isonia-
zid, rifampin, pyrazinamide, ethambutol, rifater, rifinah,
streptomycin, cycloserine, prothionamide, amikacin, kana-
mycin, ciprofloxacin, moxifloxacin, and levofloxacin) for
more than 90 days during the study period [28,29].It is possible that patients with other diseases (e.g., non-
tuberculous mycobacterial infection, lung cancer, or latent
TB infection) were misdiagnosed with active TB and put
on anti-tuberculosis medications initially. To avoid this
misclassification of outcome, we screened the NHI records
of patients who were classified as active TB cases by this
definition. If the ICD-9 codes of TB (010–018) in these
patients were replaced by those of nontuberculous myco-
bacterial infection (031), lung cancer (162), or positive tu-
berculin skin test (795.5) during subsequent follow-up
with discontinuation of anti-tuberculosis medications, the
patients would be reclassified as non-TB.
Confounders
To determine the impact of IBT on the risk of active TB,
it is important to take into consideration the influences of
known risk factors, such as HIV infection (ICD-9 code
042), silicosis (ICD-9 codes 501–504), diabetes (ICD-9
code 250), chronic obstructive pulmonary disease (COPD)
(ICD-9 codes 403, 416, 491–493, 495–495,508, 515, 516,
and 518), connective tissue disease (ICD-9 codes 710, 712,
714, 715, 716, 719, and 728), End Stage Renal Disease
(ESRD) (ICD-9 code 585.6) and malignancy (ICD-9 codes
140–239) [30]. Because smoking status was unavailable for
this database, COPD was selected as a proxy for cigarette
smoking [31]. In addition, the occurrence of cirrhosis
might impact the prognosis of HCV patients and IBT is
used with caution in patients with cirrhosis and is contra-
indicated in patients with decompensated liver disease [4].
We clarified the etiology and severity of liver disease by
code as follows: cirrhosis of the liver without mention of
alcohol (ICD-9-CM: 571.5, 571.6), alcoholic liver cirrhosis
(ALC) (571.2), other alcoholic liver diseases (571.0,
571.1,571.3), and liver cirrhosis-related complications in-
cluding ascites (789.5), esophageal varices (456.0, 456.1,
456.2) and hepatic encephalopathy (572.2). Covariates in-
cluded all variables shown in Table 1, in which diseases
were coded as yes/no and defined by ICD-9-CM codes.
Statistical analysis
All the data processing and statistical analyses were
performed with SAS 9.3 software (Cary, NC, USA). Chi-
square tests were used to compare the distributions of
categorical variables between patients who did or did
not receive IBT. The time-to-event analysis involved es-
timating the probability that an event would occur at
different points in time. The endpoint of follow-up in
the subjects developing active TB was the date of 1) hav-
ing taken two anti-TB medications for more than
90 days, and 2) having a TB-specific ICD-9 code, and
those lost to follow-up were censored on the date of last
visit, creating “censored” data. The most common time-
to-event statistical methods are Kaplan-Meier analysis
and the proportional hazards model. The Kaplan-Meier
Table 1 Characteristics of the enrolled patients
Variable Interferon-based therapy P value
Yes No
N = 621 N = 2460
Sex, n (%) 0.849
Male 351 (56.5) 1380 (56.1)
Female 270 (43.5) 1080 (43.9)
Age, n (%) 0.999
20 – 29 22 (3.5) 84 (3.4)
30 – 39 54 (8.7) 217 (8.8)
40 – 49 123 (19.8) 485 (19.7)
50 – 59 231 (37.2) 906 (36.8)
60 – 69 154 (24.8) 620 (25.2)
≧70 37 (6.0) 148 (6.0)
Comorbid disease, n (%)
Human immunodeficiency
virus infection
2 (0.3) 12 (0.5) 0.583
Chronic obstructive
pulmonary disease
41 (6.6) 128 (5.2) 0.171
Connective tissue disease 182 (29.3) 702 (28.5) 0.704
Silicosis 1 (0.2) 1 (0.04) 0.615
Diabetes mellitus 126 (20.3) 449 (18.3) 0.244
End stage renal disease 7 (1.1) 83 (3.4) *0.003
Malignancy 38 (6.1) 102 (4.1) *0.035
Liver disease, n (%)
Non-alcoholic liver cirrhosis 99 (15.9) 214 (8.7) *<0.001
Alcoholic liver cirrhosis 7 (1.1) 27 (1.1) 0.949
Other alcoholic liver disease 11 (1.8) 28 (1.1) 0.207
Liver disease severity, n (%)
Ascites 4 (0.6) 19 (0.8) 0.740
Esophageal varices 4 (0.6) 20 (0.8) 0.668
Hepatic encephalopathy 0 (0) 16 (0.7) *0.043
*means P < 0.05.
Table 2 Results of hazard ratios in IBT-treated cohorts in
1-year and long-term follow-up





Control (n = 621) 3 (0.5) 1 1
IBT-treated (n = 2640) 5 (0.2) 2.36(0.57-9.89) 2.81(0.61-12.98)
Long-term follow-up
Control (n = 621) 3 (0.5) 1 1
IBT-treated (n = 2640) 12 (0.5) 0.99(0.28-3.50) 1.02(0.28-3.78)
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hazard ratio of TB development between both cohorts.
The proportional hazards model was applied to analyze
the effect of single and multiple covariates in predicting
whether TB developed. Both short-term (1 year after index
date) and long-term (9 years after index date) follow-up
were included for analysis in this study.
Results
Baseline characteristics of the study population
Among the 699 HCV patients who received IBT, 621 pa-
tients (88.84%) were treated for a minimum of 2 months
and were therefore eligible as the IBT-treated cohort (n =
621). The control cohort comprised 2,460 untreated pa-
tients who were selected from those not receiving IBT
(Figure 1). Table 1 shows the baseline characteristics ofthe two cohorts. Most patients in both cohorts were
aged between 50 to 69 years. To compare with the un-
treated cohort, patients in IBT-treated cohort had more
malignancy and non-alcoholic liver cirrhosis. (P = 0.035
and <0.001, respectively) Patients in the untreated cohort
had more ESRD and hepatic encephalopathy (P = 0.003
and 0.043, respectively).Incidences of TB among the two cohorts
During the 9-year enrollment period, the treated and un-
treated cohorts were followed up for a mean (± SD) dur-
ation of 6.97 ± 0.02 years and 8.21 ± 0.01 years, respectively.
Among the treated cohort, which included those who had
ever received IBT for a minimum of 8 weeks, the mean
(± SD) duration of the antiviral regimen was 20.29 ±
4.50 weeks. During a 1-year follow-up, 3 patients devel-
oped TB in IBT treated cohort and 5 patients developed
TB in untreated cohort. During the long-term follow-up,
3 patients developed TB in IBT- treated cohort and 12
patients developed TB in untreated cohort. The cumula-
tive incidences of TB during this study period were 0.150
and 0.151 per 100 person-years in the IBT treated and
untreated cohorts in long-term follow-up, respectively.
There was no significant difference in the incidence of
active TB in either cohort during a 1-year follow-up
(Adjusted Hazard Ratio (AHR): 2.81, 95% Confidence
Interval (95% CI): 0.61–12.98) or the long-term follow-up
(AHR: 1.02, 95% CI: 0.28 – 3.78) (Table 2). Further ana-
lysis by the log-rank test revealed no significant difference
of the incidence of TB in both cohorts during 1-year and
long-term follow-up periods.(P = 0.261 and 0.987, respect-
ively) Figure 2 showed the crude cumulative incidence of
tuberculosis among both cohorts in 1-year follow-up.Multivariate-adjusted association of antiviral therapy with
active TB
The Cox proportional hazards model demonstrated that
IBT was not associated with active TB (Tables 3 and 4).
The only factor associated with the development of
active TB was the occurrence of hepatic encephalopathy.
(Hazard Ratio (HR):54.90 and 95% CI: 2.82–1069.53 in
Figure 2 1 minus Kaplan Meier to approximate cumulative
incidence of tuberculosis among the IBT cohort (treated) and
the untreated cohort (untreated) during 1-year follow-up (log
rank test: 1.26, P = 0.261).
Table 3 Results of the multivariate-adjusted cox proportional








Male 2.75 0.55 –13.79 0.218








Connective tissue disease 0.33 0.04- 2.78 0.309
Silicosis - - -
Diabetes mellitus 2.81 0.62 – 12.75 0.180
End stage renal disease - - -
Malignancy 1.78 0.20 – 15.69 0.602
Liver disease
Non-alcoholic liver cirrhosis 0.97 0.11–8.46 0.976





Ascites - - -
Esophageal varices - - -
Hepatic encephalopathy 54.90 2.82–
1069.53
*0.008
Interferon-based therapy 2.81 0.61–12.98 0.185
*means P < 0.05.
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in long-term follow-up).
Discussion
In this population-based cohort study, IBT was not associ-
ated with active TB in HCV patients after adjustment for
possible confounding factors, such as HIV infection, sili-
cosis, COPD, connective tissue disease and malignancy.
During the 1-year and long-term follow-up periods, the
crude cumulative TB incidences in both cohorts were not
significantly different. The incidence of TB in the IBT
treated cohort was 0.150 per 100 person-years during this
study period, which was lower than the reported incidence
rates of HIV-HCV co-infected patients receiving IBT (0.7
cases per 100 person-years) in Spain and HCV patients
(1.4 cases per 100 person-years) in Pakistan [32,33].
The role of IFNs in exacerbating TB infection remains
controversial. Few case reports have described the associ-
ation between IBT and active TB [18-22]. TB events in
clinical trials of HCV patients treated with IBT were rarely
reported. Only one study in Taiwan [34] reported 308
treatment-naive HCV-1–infected patients receiving IBT re-
sulted in one case with TB reactivation at week 32 of IBT.
Three HCV infected patients with active TB were identi-
fied in the IBT-treated cohort in this study. These TB
cases were confirmed within 38 weeks of IBT initiation.
IBT was not an independent risk factor for the develop-
ment of active TB in our study; the only risk factor re-
ported was advanced liver disease. Because of the multiple
levels of immune dysfunction, cirrhotic patients are pre-
disposed to infectious diseases, including bacterial and TB
infection [35]. In Taiwan, liver cirrhosis and chronic liverdisease were significant risk factors associated with death
in a TB infected population [36]. Our results demonstrate
that the association of hepatic encephalopathy and TB
may indicate a vulnerability to TB for cases with compro-
mised liver function. Further prospective study is neces-
sary to clarify the role of IBT in active TB cases during the
hepatitis treatment course.
The HCV shares risk factors and routes of transmis-
sion with some infectious diseases. Compared to people
without HCV infection, HCV carriers were significantly
associated with many infectious diseases, including TB
[37]. It is presumed that HCV itself is a risk factor for
TB infection regardless of whether the HCV was treated
with IBT. Although IBT is not associated with increasing
hazard of active TB in HCV infected patients in our
study, it seemed to be higher among IBT group with
one-year follow-up. It is reasonable to be careful the oc-
currence of active TB while using IBT to treat HCV in-
fected patients in one-year period. Further study to
evaluate this issue by enrolling greater sample size is
necessary.
Table 4 Results of the multivariate-adjusted cox proportional








Male 2.41 0.75 – 7.72 0.139







0.77 0.09 – 6.36 0.809
Connective tissue disease 0.36 0.08- 1.65 0.189
Silicosis - - -
Diabetes mellitus 2.01 0.67 – 6.06 0.216
End stage renal disease 1.97 0.25 – 15.63 0.522




1.48 0.30 – 7.40 0.631





Ascites - - -
Esophageal varices - - -
Hepatic encephalopathy 16.75 1.22 – 231.02 *0.035
Interferon-based therapy 1.02 0.28 – 3.78 0.974
*means P < 0.05.
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First, although we did not demonstrate an association
between IBT and active TB in this study, this lack of as-
sociation maybe related to the different TB prevalences
in the different age populations in our country. In the
IBT treated cohort, 69.2% (430/621) of patients were less
than 60 years old. However, the TB incidence rate gener-
ally increases in older population, especially in those
over 65 years old [24]. IBT in HCV infected patients in
the elderly population needs further investigation. Sec-
ond, the Taiwan NHIRD did not contain direct labora-
tory results. Therefore, we were unable to determine
how viral genotype, viral load and CD4 numbers might
influence the outcomes. Because of the limitation of this
database, there was no standard procedure for diagnosis
of TB infection (acid-fast stain, culturing and histopath-
ology). Instead, we defined TB infection according to
ICD-9-CM codes of TB with taking anti-TB medication
for more than 3 months. It is likely that some patients
with TB infections did not submit claims for medication,
or died before 3 months of treatment, which mayunderestimate the total number of MTB infected pa-
tients. Third, some patients were treated with corticoste-
roids, which are known to increase the risk of TB [38].
Although we adjusted for patients with connective tissue
diseases and COPD, a proportion of the patients exposed
to corticosteroids would be underestimated. Finally, this
study lacked information on several important risk fac-
tors, such as smoking, nutritional status, intravenous
drug abuse, and occupational exposure, which are also
not available in the NHIRD.
Conclusion
Our results showed that IBT is associated with increased
hazard of active TB in HCV infected patients in 1-year
follow-up; however, the effect sizes were not statistically
significant.
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